<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1942">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382066</url>
  </required_header>
  <id_info>
    <org_study_id>APL-D-002-20</org_study_id>
    <secondary_id>2020-001993-31</secondary_id>
    <nct_id>NCT04382066</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19</brief_title>
  <acronym>APLICOV-PC</acronym>
  <official_title>Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of&#xD;
      pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome&#xD;
      information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a&#xD;
      real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay.&#xD;
&#xD;
      Given no specific antiviral therapy for COVID-19 and the ready availability of plitidepsin as&#xD;
      a potential antiviral agent, based on pre-clinical studies, this randomized, parallel and&#xD;
      proof of concept trial will evaluate the safety of three doses of plitidepsin in patients&#xD;
      hospitalized with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Last December, a new infectious respiratory disease emerged in Wuhan, China. The agent that&#xD;
      caused this pneumonia was identified as a new virus in the Coronaviridae family (SARS-CoV-2)&#xD;
      and the clinical symptomatology associated with the virus has been named COVID-19. COVID-19&#xD;
      is currently a public health emergency.&#xD;
&#xD;
      Plitidepsin is an authorized drug in Australia for the treatment of multiple myeloma.&#xD;
      Antiviral activity of plitidepsin has been analyzed in a human hepatoma cell line infected&#xD;
      with the HCoV-229E-GFP virus, a virus similar to the SARS-CoV-2 virus.&#xD;
&#xD;
      Taking into account that the available safety data from plitidepsin comes from patients with&#xD;
      solid tumors that received treatment with a regimen of administration of plitidepsin for 5&#xD;
      consecutive days, we propose a multicenter, randomized, proof-of-concept clinical trial to&#xD;
      assess the safety profile of 3 different dose levels of plitidepsin administered three&#xD;
      consecutive days, in adult patients with confirmed diagnosis of COVID-19 who require hospital&#xD;
      admission.&#xD;
&#xD;
      This study aims to assess safety and toxicity profile and also preliminary efficacy of&#xD;
      plitidepsin at each dose level administered according to the proposed administration scheme&#xD;
      in patients with COVID-19 who require hospital admission. Main objective is to select the&#xD;
      recommended dose levels of plitidepsin for a future phase II / III efficacy study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Actual">December 23, 2020</completion_date>
  <primary_completion_date type="Actual">December 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence of Neutropenia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Neutropenia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Thrombocytopenia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Thrombocytopenia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Anemia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Anemia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Lymphopenia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Lymphopenia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of CPK increase ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with CPK increase ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Increase ALT and / or AST ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Increase ALT and / or AST ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Increase total bilirubin or direct bilirubin ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Increase total bilirubin or direct bilirubin ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Neurotoxicity ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Neurotoxicity ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of QT-QTc interval extension ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with QT-QTc interval extension ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Other adverse events ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Other adverse events ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients in whom treatment cannot be completed.</measure>
    <time_frame>At 3 days from the first dose of study treatment</time_frame>
    <description>Percentage of patients in whom treatment cannot be completed and the reasons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with adverse events.</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with serious adverse events.</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with ECG abnormalities.</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with ECG abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the viral load of SARS-CoV-2</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of change in the viral load of SARS-CoV-2 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative PCR test for COVID-19</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Time from inclusion/randomization to date of negative PCR test for COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients who die during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring invasive mechanical ventilation and / or ICU admission</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients requiring invasive mechanical ventilation and / or ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring non-invasive mechanical ventilation</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients requiring non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring oxygen therapy</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients requiring oxygen therapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin 1.5 mg / day x 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin 2.0 mg / day x 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin 2.5 mg / day x 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 1.5 mg/day</intervention_name>
    <description>Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 2.0 mg/day</intervention_name>
    <description>Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 2.5 mg/day</intervention_name>
    <description>Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.</description>
    <arm_group_label>Experimental 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient who agrees to participate in the study by signing the informed consent.&#xD;
&#xD;
          2. Men and women (non-pregnant) aged ≥18 years.&#xD;
&#xD;
          3. COVID-19 infection confirmed by PCR obtained from nasopharyngeal exudate or sample&#xD;
             from the lower respiratory tract.&#xD;
&#xD;
          4. Patients who require hospitalization for COVID-19.&#xD;
&#xD;
          5. Symptom onset at most within 10 days prior to study inclusion.&#xD;
&#xD;
          6. Men and women with reproductive capacity should agree to use highly effective&#xD;
             contraceptive methods during their participation in the study and in the 6 months&#xD;
             following the last administration of plitidepsin.&#xD;
&#xD;
          7. In addition, women participating in the study with reproductive ability must have a&#xD;
             negative pregnancy test at enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients participating in some other clinical trial for COVID-19 infection.&#xD;
&#xD;
          2. Patients who are receiving treatment with antivirals, interleukin 6 receptor&#xD;
             inhibitors or immunomodulatory drugs for COVID-19.&#xD;
&#xD;
          3. Patients who are receiving treatment with chloroquine and derivatives.&#xD;
&#xD;
          4. Evidence of multi-organ failure.&#xD;
&#xD;
          5. Patients who require support with mechanical ventilation (invasive or non-invasive) at&#xD;
             the time of inclusion.&#xD;
&#xD;
          6. D-dimer&gt; 4 x UNL.&#xD;
&#xD;
          7. Hb &lt;9 g / dL.&#xD;
&#xD;
          8. Neutrophils &lt;1000 / mm3.&#xD;
&#xD;
          9. Platelets &lt;100,000 / mm3.&#xD;
&#xD;
         10. Lymphopenia &lt;800 / μL.&#xD;
&#xD;
         11. GOT / GPT&gt; 3 X UNL.&#xD;
&#xD;
         12. Bilirubin&gt; 1 X UNL.&#xD;
&#xD;
         13. CPK&gt; 2.5 X UNL.&#xD;
&#xD;
         14. Creatinine clearance &lt;30ml / min.&#xD;
&#xD;
         15. Troponin elevation&gt; 1.5 x ULN.&#xD;
&#xD;
         16. Clinically relevant heart disease (NYHA&gt; 2).&#xD;
&#xD;
         17. Clinically relevant arrhythmia or previous history / presence of prolonged QT-QTc ≥&#xD;
             450 ms.&#xD;
&#xD;
         18. Pre-existing neuropathies of any type ≥ grade 2.&#xD;
&#xD;
         19. Hypersensitivity to the active substance or to any of its excipients (macrogol&#xD;
             glycerol ricinoleate and ethanol).&#xD;
&#xD;
         20. Patients who require or are being treated with potent CYP3A4 inhibitors and inducers.&#xD;
&#xD;
         21. Patients who for any reason should not be included in the study according to the&#xD;
             evaluation of the research team.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Estrada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Fortún, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Barberán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO HM MONTEPRÍNCIPE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Hm Montepríncipe</name>
      <address>
        <city>Boadilla Del Monte</city>
        <state>Madrid</state>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Quironsalud Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plitidepsin</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Coronavirus</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data of the final publication of the study will be shared upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

